Medline price target raised to $55 from $50 at Evercore ISI

Evercore ISI raised the firm’s price target on Medline (MDLN) to $55 from $50 and keeps an Outperform rating on the shares. The firm notes Medline exited FY25 with strong momentum, delivering Q4 net sales of $7.8B on broad-based strength across both segments. Importantly, the company closed the year with $2.4B of new customer signings, providing meaningful forward revenue visibility.